Correction: Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

review OA: gold CC0
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-07-26 ⓘ

This correction announces that the review of relugolix/estradiol/norethisterone acetate for endometriosis-associated pain has been made open access, funded by Sumitomo Pharma and Pfizer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-21 · read from full text ⓘ

This document is a formal correction notice published in the journal Drugs, addressing the original review article titled "Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain" by Hannah A. Blair. The primary change involves updating the publication status from closed access to Open Access, funded by Sumitomo Pharma Switzerland GmbH and Pfizer, while retaining the original content and license terms. No scientific findings or clinical data are presented within this specific text, as it serves solely to amend copyright and accessibility metadata for the previously published work. This paper is centrally about endometriosis — specifically serving as the administrative correction record for a drug review focused on treating pain associated with that condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,909 characters · extracted from oa-pdf · click to expand
Vol.:(0123456789) Drugs (2024) 84:623 https://doi.org/10.1007/s40265-024-02050-3 CORRECTION Correction: Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis‑Associated Pain Hannah A. Blair1 Accepted: 16 May 2024 / Published online: 30 May 2024 © The Author's 2024 Correction: Drugs (2024) 84:449–457 https://doi.org/10.1007/s40265-024-02018-3 The article Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain, written by Han- nah A. Blair, was originally published Online First with- out Open Access. After publication in volume 84, issue 4, pages 449–457, Sumitomo Pharma Switzerland GmbH and Pfizer requested that the article be Open Choice to make the article an Open Access publication. Post-publication open access was funded by Sumitomo Pharma Switzerland GmbH and Pfizer. This article is licensed under a Creative Commons Attri- bution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, dis- tribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the arti- cle’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by- nc/4. 0/. The original article has been corrected. Open Access This article is licensed under a Creative Commons Attri- bution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com- mons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regula- tion or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by- nc/4. 0/. The original article can be found online at https:// doi. org/ 10. 1007/ s40265- 024- 02018-3. * Hannah A. Blair [email protected] 1 Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-pdf ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-10-05T06:18:27.067365+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-05T06:16:08.524559+00:00
License: CC0 · commercial use OK